Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

"3T is tackling one of the toughest challenges in immuno-oncology: delivering potent, selective TCR therapies for solid tumors," said Dr. Knudsen. "The science is compelling, and the opportunity for ...

Cold Spring Harbor Laboratory researchers reveal a groundbreaking approach using CAR T-cell therapy to rejuvenate aging ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

The Postdoctoral Scholar will lead innovative research projects focused on the development and evaluation of immunotherapies for brain tumors, with an emphasis on CAR-T cell therapy. This position ...

After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel like they have “brain fog,” or forgetfulness and difficulty concentrating. A ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led ...